Investors are watching Beijing’s annual “two sessions” this week for signs that the country will address drug pricing and shore up its drug payment system, as a new form of insurance introduced in January for expensive, innovative treatments struggles to gain traction.
Near-term policy impact on the sector was likely to be limited, analysts said ahead of the annual meetings of China’s top legislature and political advisory body, which begin in Beijing on Wednesday.
“We are not expecting much groundbreaking news related to healthcare from the two sessions,” said Tony Ren, head of Asia healthcare research at Macquarie Capital. “The impact tends to be moral support rather than concrete results.”
Zhang Jialin, Nomura’s head of China healthcare research, said the meetings could yield fine-tuning on certain policies like volume-based procurement (VBP) and commercial insurance, but nothing that would have “immediate material impact on listed companies’ financials”.
The National People’s Congress is expected to review a draft outline for the nation’s 15th five-year plan for 2026 through 2030, which supports innovative drug development and identifies biomanufacturing as a new engine of economic growth.
“The market is looking for a mildly supportive policy tone towards China healthcare at the two sessions, especially around innovative drug research and development, drug pricing policy and commercial health insurance,” said Cui Cui, head of healthcare research for Asia at Jefferies.
Zhang Jialin, commercial health insurance, Jefferies, volume-based procurement, National People's Congress, Nomura, Beijing, Eisai, China, Asia Healthcare Research, drug pricing pressures, China International Capital Corporation, Macquarie Capital, Cui Cui, National Healthcare Security Administration#Healthcare #investors #keeping #eye #sessions #clarity #drug #pricing1772585664
Asia Healthcare Research
Beijing
China
China International Capital Corporation
Clarity
commercial health insurance
Cui Cui
Drug
drug pricing pressures
Eisai
Eye
healthcare
investors
Jefferies
keeping
Macquarie Capital
National Healthcare Security Administration
National People's Congress
Nomura
pricing
sessions
volume-based procurement
Zhang Jialin
